81 related articles for article (PubMed ID: 34128042)
1. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
Giuliani J; Mantoan B; Mangiola D; Muraro M; Napoli G; Tommasi M; Fiorica F; Mandarà M
Clin Colorectal Cancer; 2024 Mar; 23(1):1-3. PubMed ID: 37932152
[No Abstract] [Full Text] [Related]
3. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis.
Aquino de Moraes FC; Dantas Leite Pessôa FD; Duarte de Castro Ribeiro CH; Rodrigues Fernandes M; Rodríguez Burbano RM; Carneiro Dos Santos NP
BMC Cancer; 2024 Jun; 24(1):674. PubMed ID: 38825703
[TBL] [Abstract][Full Text] [Related]
4. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.
Narita Y; Ogata T; Ishizuka Y; Sakakida T; Wakabayashi M; Kodama H; Honda K; Masuishi T; Taniguchi H; Kadowaki S; Ando M; Tajika M; Muro K
Sci Rep; 2024 Jun; 14(1):12658. PubMed ID: 38830895
[TBL] [Abstract][Full Text] [Related]
6. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Okunaka M; Kawazoe A; Nakamura H; Kotani D; Mishima S; Kuboki Y; Nakamura Y; Shitara K
Gastric Cancer; 2023 Nov; 26(6):1030-1039. PubMed ID: 37665515
[TBL] [Abstract][Full Text] [Related]
8. Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.
Kashiwa M
Eur J Health Econ; 2024 Apr; 25(3):459-470. PubMed ID: 37261572
[TBL] [Abstract][Full Text] [Related]
9. Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis.
Prejac J; Omrčen T; Radić J; Vrdoljak E; Fröbe A; Pleština S
Oncology; 2024; 102(3):217-227. PubMed ID: 37699377
[TBL] [Abstract][Full Text] [Related]
10. Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer-A Single UK Centre Experience.
Tong D; Wang L; Mendis J; Essapen S
Curr Oncol; 2021 Jun; 28(3):2260-2269. PubMed ID: 34207352
[TBL] [Abstract][Full Text] [Related]
11. Improving survival in metastatic colorectal cancer through optimized patient selection.
Bekaii-Saab TS; Barzi A; Cusnir M
Clin Adv Hematol Oncol; 2024 Jun; 22 Suppl 4(5):1-20. PubMed ID: 38805297
[TBL] [Abstract][Full Text] [Related]
12. Sequencing considerations in the third-line treatment of metastatic colorectal cancer.
Barzi A; Bekaii-Saab T
Am J Manag Care; 2024 May; 30(2 Suppl):S31-S35. PubMed ID: 38701364
[TBL] [Abstract][Full Text] [Related]
13. Trifluridine/tipiracil plus ramucirumab in gastric cancer.
Zhu M; Sonbol MB; Yoon HH
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):154-155. PubMed ID: 33508243
[No Abstract] [Full Text] [Related]
14. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
Botsen D; Chabaud S; Perrier H; Ammarguellat H; Jestin-Le-Tallec V; Olesinski J; Toullec C; Aparicio T; Ben Abdelghani M; Borg C; Bouche O; Coutzac C; Devaud H; Di Fiore F; Dubreuil O; Evesque L; Huguenin B; Muller M; Poureau PG; Oularue E; Tougeron D; Zaanan A; Ammari S; De Sousa Carvalho N; Decazes P; De La Fouchardiere C
Dig Liver Dis; 2024 May; ():. PubMed ID: 38762353
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of surveillance intervals after curative resection of colorectal cancer.
Takayama Y; Tsukamoto S; Kudose Y; Takamizawa Y; Moritani K; Esaki M; Kanemitsu Y; Igarashi A
Jpn J Clin Oncol; 2024 Jun; 54(6):637-646. PubMed ID: 38376792
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry.
Koganemaru S; Fuchigami H; Yamashita H; Morizono C; Sunakawa H; Kawazoe A; Nakamura Y; Kuboki Y; Shitara K; Yano T; Doi T; Yasunaga M
Clin Pharmacol Ther; 2024 Jan; 115(1):62-70. PubMed ID: 37803526
[TBL] [Abstract][Full Text] [Related]
17. Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y; Ito N; Mimura Y; Sugiyama Y; Ogawa R; Shimura T; Nakamura M; Kawakita D; Hamamoto S; Uemura T; Yokota K; Iida M; Odagiri K; Kimura Y; Hotta Y; Komatsu H; Okuda K; Niimi A; Yasui T; Iwasaki S; Morita A; Kataoka H; Takiguchi S; Furukawa-Hibi Y
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38682421
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population.
Petrillo A; Tirino G; Zito Marino F; Pompella L; Sabetta R; Panarese I; Pappalardo A; Caterino M; Ventriglia A; Laterza MM; Morgillo F; Orditura M; Ciardiello F; Franco R; De Vita F
Onco Targets Ther; 2020; 13():867-876. PubMed ID: 32099391
[TBL] [Abstract][Full Text] [Related]
19. Lonsurf (Trifluridine plus Tipiracil): A New Oral Treatment Approved for Patients with Metastatic Colorectal Cancer.
Raedler LA
Am Health Drug Benefits; 2016 Mar; 9(Spec Feature):97-100. PubMed ID: 27668054
[No Abstract] [Full Text] [Related]
20. The cost of schizophrenia in Japan.
Sado M; Inagaki A; Koreki A; Knapp M; Kissane LA; Mimura M; Yoshimura K
Neuropsychiatr Dis Treat; 2013; 9():787-98. PubMed ID: 23785238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]